drugset / Trial / NCT00483717

Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine

NCT00483717

Phase 2 Completed 173 enrolled Egalet Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The study evaluates the efficacy and safety of using ketorolac as a nasal spray for the acute treatment of migraine.

Timeline

Start
2007-07
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Tromethamine Small molecule 31.5 mg Intranasal
Background Lidocaine Other / unclassified 6 % Intranasal

Indications